Wearables, Measurements, and Meaning: Women’s Health Data Across the Life Course
Heart rate, skin temperature and sleep trends can add context. A score cannot stand in for hormone levels, menopause diagnosis or how rested you feel.

In this article
Written October 23, 2026 | Research perspective: wearable devices × women’s health across the life course. For industry observers, health-management practitioners, clinician readers, and women aged 40+ interested in their own health data.
⚠️ Scope statement—please read first: the devices discussed here are consumer-grade or for general health reference. Their data do not replace medical devices and do not constitute a basis for clinical diagnosis or treatment. Decisions about medication, including MHT/hormone therapy, pregnancy planning, contraception, and disease management must rely on a treating clinician’s interpretation of laboratory and imaging findings. Product specifications should be checked against official manufacturer releases. Several 2026 products were announced but not yet on sale or remained in testing; verify availability again before buying.
0. Why now? Three premises
- Demand: reproductive health, sleep, mood, and menopause management have long suffered from fragmented data. Manual temperature records and menstrual calendars struggle to provide a continuous picture.
- Technology: miniature sensors, flexible batteries, and low-energy Bluetooth matured together in 2024–2026, moving wearables beyond watches and bands toward a surge in rings.
- Market: industry research reports 128% year-on-year growth in domestic smart-ring retail sales in the first half of 2026, with shipments exceeding ten million units. Worldwide shipments were around 24 million in 2025 and projected at 38–42 million in 2026. Market value was approximately US$4.17 billion in 2025, potentially reaching US$37.7 billion by 2034, a CAGR of about 29.3%.
In one sentence: women’s health is moving from an additional wearable feature to an independent strategic market.
I. Mainstream wearable data capabilities in five dimensions
1. Menstrual cycles and reproductive health
| Capability | How it works | Representative products |
|---|---|---|
| Period prediction | Wrist/skin-temperature trends plus calendar algorithms | Apple Watch, Oura, Garmin, Xiaomi, OPPO |
| Ovulation window / retrospective fertile-day estimation | Biphasic basal-temperature pattern, rising 0.3–0.5°C after ovulation, combined with HRV/resting heart rate | Oura Cycle Insights, Natural Cycles integration, Ava, Tempdrop |
| Perimenopause/menopause indications | Long-term deviations in temperature and cycle regularity | Apple Watch perimenopause indications, Oura Menopause Insights |
| Ovarian-health assessment | Modeling over 14–35 consecutive days | Huawei WATCH GT 7, described as a class II medical device |
| Pregnancy monitoring | Temperature combined with symptoms and activity | Oura Pregnancy Insights, Evie |

Gravdalsbukta, Reine, Norway | Photograph:
Simo Räsänen
,
CC BY-SA 4.0
Key mechanism: skin temperature is described here as the only measurement that can capture ovulation signals passively, continuously, and unobtrusively. Stable finger contact gives rings more consistent temperature measurement than wrist devices, a point emphasized by RingConn and Oura.
2. Sleep
- Sleep staging, including deep, REM, and light sleep: Oura Ring 5 claims 95% accuracy against a clinical sleep laboratory; Huawei, Garmin, and Apple all provide sleep scores.
- HRV, resting heart rate, and respiratory rate: continuous baselines inform recovery and possible early illness detection.
- Sleep-apnea notifications: Apple Watch Series models and Samsung watches have received FDA De Novo clearance, described here for moderate-to-severe apnea over a two-night window.
- Temperature trends: support cycle assessment and Illness Detection.
3. Heart rate and cardiovascular health
- 24/7 heart rate: a basic capability across mainstream devices.
- ECG/atrial-fibrillation screening: Apple Watch, Huawei ECG Pro, and Samsung watches.
- Hypertension notifications: Apple Watch Series 11 adds trend-based hypertension warnings, rather than individual blood-pressure readings.
- Cardiovascular age/estimated VO2 Max: Oura Ring 5 Cardiovascular Age and Cardio Capacity.

Bryggen, Bergen, Norway | Photograph:
Diego Delso
,
CC BY-SA 4.0
4. Mood and stress
| Technology | Principle | Representative example |
|---|---|---|
| HRV | Proxy for autonomic balance; lower HRV suggests inadequate recovery/stress | All device categories |
| EDA/cEDA, electrodermal activity | Direct measurement of sympathetic arousal | Fitbit Sense 2 electrodermal sensor |
| Daytime Stress / Resilience | Multiple signals combined into daytime/nighttime stress patterns | Oura Ring 5 |
| Vagus nerve stimulation, VNS | Active intervention rather than monitoring alone | OhmBody dedicated auricular-stimulation device |
| Strain/Recovery | Training load compared with recovery | WHOOP, subscription-only model |
5. Exercise and activity
- Automatic activity detection: Oura Ring 5 recognizes over 40 activities; Apple and Garmin have established exercise modes.
- Personalized activity goals: adjusted to daily recovery, such as Oura Readiness-driven goals.
- Pelvic-floor/Kegel training: dedicated Perifit and Elvie products with pressure-sensor feedback.
II. Technical development and future product directions
Trend 1: dedicated women’s-health scenarios become independent products
Earlier approaches changed a general device’s color and added a period log. In 2025–2026, Oura introduced its first proprietary women’s-health AI model, spanning menstruation through menopause. Ultrahuman incorporated OvuSense training data from more than 260,000 cycles; brands such as QKeer retrained algorithms specifically for East Asian women. Women’s health is becoming a core product line rather than an add-on.

Skógafoss, Iceland | Photograph:
JavierOlivares
,
CC BY-SA 4.0
Trend 2: continuous hormone and metabolic monitoring—the next decade’s frontier
- CGM integration: Oura Ring 5 supports CGM Integration and GLP-1 Insights for metabolic health.
- Microneedle continuous hormone biosensors: startups such as Clair are investigating subcutaneous continuous estrogen/progesterone measurement.
- Home urine-hormone monitoring: Mira measures LH/E3G/PdG/FSH; kegg measures cervical-fluid electrolytes, moving laboratory-style information into the home.
Trend 3: digital twins and GenAI coaches
Oura’s Symptom Radar / Health Radar proactively flags signs of bodily strain. Its women’s model combines clinical standards, peer-reviewed evidence, and user biometrics to produce personalized guidance. AI is moving from data recording toward active intervention and abnormality alerts.
Trend 4: Clinic-at-Home and remote chronic-disease management
Professional services are beginning to use continuous ring/band data. Public reports state that Beijing Obstetrics and Gynecology Hospital has incorporated smart-ring data into its women’s whole-life-course health-management guidance. Wearables are becoming an extension of monitoring beyond the hospital.
Trend 5: autonomic and vagal-tone markers
Emotional health is moving from questionnaires toward physiological markers combining HRV, EDA, and breathing. Fitbit cEDA, WHOOP recovery, and OhmBody vagal stimulation point toward quantifying and influencing otherwise invisible stress.
Trend 6: new form factors and the smart-ring surge
Light weight, unobtrusive wear, and 5–10-day battery life address the discomfort of sleeping in a watch. The source calls 2026 the first major year of rings, while warning that marketing may outpace validation. Noninvasive glucose rings displayed at CES 2026 remained research devices and were not expected to launch in 2026.
Trend 7: correcting the gender data gap
Caroline Criado Pérez’s Invisible Women explains how health algorithms often use male bodies as their normal baseline. A female Ivy League academic reportedly found that Oura labeled her body abnormal on the same days each month, when she was simply menstruating. Future advantage lies in baselines incorporating normal female-cycle variation and region-specific physiological retraining, rather than additional sensors alone.

Stockholm City Hall waterfront, Sweden | Photograph:
Holger.Ellgaard
,
CC BY-SA 3.0
Trend 8: tighter regulation and clearer boundaries
- The US FDA released draft intended-use guidance for nonprescription health wearables in early 2026.
- The EU proposed clarification of smart rings under Medical Device Regulation, MDR, boundary guidance.
- This separates general reference claims from claims about diagnosis, contraception, or treatment.
III. Women’s-health wearable product comparison
Table 3.1 General-purpose watches, bands, and rings
| Product | Intended users | Main women’s-health features | Technology | Distinctive advantage | Price/subscription |
|---|---|---|---|---|---|
| Apple Watch, Series 11/12 and Ultra 3/4 | Apple ecosystem and general-health users | Period/fertile-window/perimenopause indications; ECG; hypertension and apnea notifications | Wrist temperature; Vitals app for heart rate, breathing, temperature, oxygen, sleep, HRV | Broad ecosystem and extensive clinical evidence | Expensive hardware; no mandatory subscription |
| Oura Ring 5 | Health-literate women across pregnancy planning, pregnancy, and menopause | Cycle Insights, Pregnancy/Menopause Insights, Natural Cycles | Skin temperature, 50+ metrics; claimed sleep accuracy 95% versus laboratory and HR 99% versus ECG | Unobtrusive ring, women’s AI model, CGM/GLP-1 integration | US$399–499 plus US$5.99/month; HSA/FSA eligible |
| Samsung Galaxy Ring 2, announced CES 2026, H2 2026 launch | Samsung/Android ecosystem | Cycles, sleep, conceptual continuous blood pressure, stress | Titanium, ~10-day battery; continuous-BP sensor concept | Claimed first consumer continuous-BP ring, awaiting independent validation; digital car/home key | About ₹25,000 / £400–450; strongest integration needs Samsung phone |
| Garmin | Active women | Menstrual/pregnancy/menopause tracking and stage-specific food/exercise guidance | Skin temperature, Firstbeat sleep score, Connect IQ | Established sports science; no subscription | Mid/high price; no subscription |
| Huawei WATCH GT 7 | Women in China, smaller wrists | Ovarian-health assessment over 14–35 days, described as class II; emotional-health assistant; ECG Pro | Xuanji sensing, hyperglycemia-risk assessment | 41-mm option and localized compliance | Mid/high price |
| Xiaomi Watch S5 / bands | Value-focused users | Cycle/ovulation prediction, approximately 92%; one-touch health scan | Four-light/four-photodiode sensor | Low price and ecosystem | Affordable |
| OPPO Watch X3 Mini | Women with small wrists | Cycle-based exercise guidance; wrist temperature ±0.1°C | Class II medical-device certification | Compliance and smaller case | Mid-range |
| RingConn | Value/no-subscription users | Four cycle phases; 0.1°C-level temperature | Stable finger contact, long battery | No subscription; favorable accuracy reputation | About RMB 2,150 |
| Ultrahuman | Pregnancy planning/data enthusiasts | Cycle & Ovulation Pro using OvuSense; >90% ovulation confirmation; Clue integration | Trained on 260,000+ cycles; Cycle Flags for unusual patterns | No subscription; PCOS-pattern detection | About RMB 2,400 |
| Dreame Glow AI Ring | Domestic premium segment | ECG, PPG, temperature | ECG in an RMB 1,799 price band | Lower-priced ECG ring | RMB 1,799 |
| Amazfit Helio Ring 2, CES 2026 | Exercise recovery | Improved temperature sensor, continuous SpO2 | No subscription | US$150–170 range and improved temperature precision | Not yet launched |

Gamla Stan, Stockholm, Sweden | Photograph:
Richardmaackphotography
,
CC BY 4.0
Table 3.2 Dedicated women’s-health wearables
| Product | Position | Main capability | Medical support/features |
|---|---|---|---|
| Bellabeat → Ivy AI | Women’s-health AI infrastructure | Cycles, stress, sleep, activity | Moving from jewelry-like devices to an AI health assistant |
| Ava Fertility Bracelet | Pregnancy planning | Five parameters: body temperature, HR, HRV, skin temperature, sweating | FDA clearance; approximately 90% fertile-window accuracy |
| Tempdrop | Basal temperature for pregnancy planning | Continuous armband temperature | Addresses gaps in morning oral-temperature records |
| Mira | Hormone monitoring | Quantitative urine LH/E3G/PdG/FSH | Laboratory-style hormone measurements at home |
| kegg | Fertility | Cervical-fluid electrolytes and fertile window | Electrochemical sensing |
| Daysy | Natural contraception | Temperature algorithm | Positioned as class II |
| Perifit / Elvie | Pelvic-floor rehabilitation | Kegel pressure feedback | Postpartum and urinary-leakage rehabilitation |
| Bloomlife | Contractions | Pregnancy contraction monitoring | Dedicated pregnancy use |
| Clair | Frontier continuous hormones | Subcutaneous microneedle estrogen/progesterone measurement | Research-stage, not consumer-ready |
| OhmBody | Emotional-health intervention | Auricular vagus stimulation | Active intervention, not monitoring alone |
IV. Editorial directions for this publication
Given a focus on women aged 40+ and a readership including many doctors, the research suggests five practical topics:
- Can your watch monitor menopause? Explain mechanisms and error boundaries behind perimenopause indications, temperature trends, and sleep staging, alongside the MHT series.
- Invisible women: the gender data gap in algorithms. Use the reported Oura menstrual misclassification to explain male-baseline bias in accessible, relatable terms.
- Fertility rings: valuable tools or expensive promises? Examine continuous versus morning oral temperature and figures such as Natural Cycles’ 93% effectiveness, emphasizing appropriate tool use and shared clinical decisions.
- Will a doctor use wearable data? Starting from the Beijing hospital guidance report, explain how services use out-of-clinic data, what is informative, and what cannot replace laboratory tests.
- Should you wear a device during MHT? Explain that trends may be observed but wearable data cannot assess treatment efficacy or risk, consistent with this publication’s MHT boundaries.

Lofoten, Norway | Photograph:
Russo Francesco
,
CC BY 3.0
All topics should follow this publication’s editorial rules: use MHT instead of HRT; do not sell medicines; focus on informed participation, bringing records to appointments, and shared decisions; keep brand names out of main educational prose; avoid formulaic nighttime or Wednesday-institution openings.
V. Conclusions
The trend in one sentence: women’s-health wearables are evolving from a period icon on a watch into a smart-ring-based data companion across the life course, with continuous, unobtrusive, specialized measurement; the decisive distinction is whether normal female-cycle variation is incorporated into the baseline, not the number of sensors.
Three practical suggestions for readers: 1. Choose the form for the use: rings for sleep/cycles because of comfort and stable temperature; watches for exercise/ECG. 2. Consider subscription and ecosystem: Oura has broad capabilities but a monthly fee; RingConn/Ultrahuman have no subscription and substantive fertility data; Galaxy Ring 2 needs a Samsung phone for full integration. 3. Respect the boundary: readings provide trends only. Pregnancy planning, contraception, MHT, and disease care belong in clinical decisions. Data are an ally, not a doctor.
Appendix: sources and limits
- Oura official site, ouraring.com, Ring 5 product page and 2026 buying guide.
- Samsung Galaxy Ring 2: CES 2026 coverage from Smart Ring HQ and technology media. As of October 2026, an H2 launch was still expected; some sources said July Unpacked did not officially launch it. Check official information when purchasing.
- Smart-ring market data: industry research compilations, including ZVZO consulting, Shanghai smart-wearables exhibition coverage, and 21st Century Business Herald’s women’s-market reporting.
- Comparative women’s-health features: WeChat article on fertility rings, including hands-on Oura/Ultrahuman/RingConn/QKeer/Evie comparisons.
- Regulation: early-2026 FDA draft nonprescription wearable guidance; proposed EU MDR boundary clarification.
- Gender data gap: Caroline Criado Pérez’s Invisible Women and examples reported by 21st Century Business Herald.
Some market figures/growth rates are secondary citations with differing definitions. Features change. This is a snapshot dated October 23, 2026, not buying advice.
Read the source material
- American Academy of Sleep Medicine: Consumer sleep technology position statement
- Apple: Cycle Tracking use and limitations
The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.
A good question starts a conversation.
Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.


